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LETTER TO THE EDITOR

Potential for stimulating host anti-tumor immune response via
RNAi-mediated local FOXP3 knockdown
Cancer Gene Therapy (2007) 14, 519–520. doi:10.1038/sj.
cgt.7701043; published online 16 March 2007

Neoplastic growths represent a unique challenge for the host
immune system. As they are indeed derived from self, many
of the same mechanisms operating to prevent autoimmunity
also provide an umbrella beneath which malignant cells are
free to proliferate.1 Central among these immune regulatory
boundaries are an influential subset of lymphocytes known
as T regs. Hypothesized to exist decades ago, yet eluding
definitive characterization until relatively recently, T regs
have been demonstrated to play a crucial role in the proper
functioning of the immune system as a whole. They may
also, however, represent one of the primary obstacles to
successful anti-tumor immunotherapies.
The T regulatory class of lymphocytes, can itself be
subdivided into several distinct populations, each possessing the ability to suppress the immune response through
a variety of often overlapping methods. Some of these
subgroups are inducible through humoral cues present
within the local microenvironment, as well as via direct
cell to cell interactions. Others are assigned more
permanent roles during thymic maturation. To date, the
surface marker most frequently associated with thymic
derived T regs, is the high-affinity a chain of the IL-2
receptor, CD25. Multiple experiments have confirmed
that depletion of lymphocytes displaying this molecule
leads to an increase in immune mediated tumor rejection.2–4 However, CD25 is not an absolute marker for
regulatory activity in vivo. It is also found on the surface
of activated effector T cells. In addition, lymphocytes
capable of regulatory activity, yet lacking CD25, have
been isolated.5 Thus, lympho-depletion of CD25 þ cells,
although offering proof of principle, may also be
counterproductive owing to the elimination of potentially
tumor reactive effector cells.
The forkhead family transcriptional regulator FOXP3
appears to be a more reliable marker of regulatory
potential. It does not, however, define the entire
regulatory pool, as some non-FOXP3 expressing suppressor cells have been characterized. However, FOXP3dependent T regs seem to play a major role in establishing
self-tolerance. This is most clearly demonstrated by the
fatal human autoimmune disorder IPEX (immunodysregulation, polyendicronopathy, enteropathy, Xlinked), which is caused by mutations in the FOXP3
gene. Besides its integral role in the thymic development
and function of mature T regs, FOXP3 has also been

found, to directly suppress the transcription of cytokines
responsible for initiating and perpetuating an effective
immune response, in cells targeted for regulatory suppression.6 This normally beneficial physiological repression of
potentially self-reactive lymphocytes may have lethal
consequences in the pathological context of malignancy.
Owing to the intracellular localization of FOXP3,
however, it is not readily accessible using traditional
methods of in vivo targeting. The recent emergence of
RNAi offers a novel opportunity for post-transcriptional
suppression of foxp3 production in vivo. Several traits of
RNAi technologies, in their current state, bode well for
the potential applicability of this tool toward in vivo
suppression of T reg activity. First, the transient nature of
knockdowns mediated by pre-synthesized small interfering RNAs, would be advantageous in a clinical setting,
allowing for the suppression of regulatory cells, only
as long as therapeutically necessary. Second, though
advances in systemic delivery are emerging at a rapid
pace, effective local transfection in vivo is still much more
readily achievable. Experimental evidence indicates that
FOXP3-dependent T regs exert much of their suppressive
effects intratumorally and within the draining lymph
nodes.1,4 Quantitative measurements of T reg presence
within tumor ascites has revealed a negative correlation
between the number of these cells present and patient
survival in ovarian carcinoma.1 Thus local transfection,
focused upon a single tumor and its draining lymph
nodes, might serve as an apt starting point for testing the
impact of RNAi mediated FOXP3 knockdown upon
tumor immunity. The greatest advantage of this technique
lies in its ability to repress regulatory pathways without
depleting effector lymphocytes.
Recent evidence indicates that inhibiting cell-mediated
immune tolerance can work synergistically with concurrent exposure to relevant tumor antigens.7,8 This illustrates the fact that regulatory cells can be seen as shielding
neoplasms, through dominant tolerance, from immunotherapies, which seek to activate tumor reactive effector
lymphocytes. FOXP3 expressing regulatory cells are also
believed to interact with dendritic cells to promote
suppression of the immune response.
As mentioned earlier, not all regulatory cells express
FOXP3. The existence of a peripherally induced subset, of
IL-10 secreting, CD-8 þ lymphocytes capable of regulatory
activity, independent of FOXP3, has recently been observed.
It has been demonstrated in vitro that these cells can be
induced via the actions of plasmacytoid dendritic cells.9 This
was found to be possible even in the absence of CD-25 þ
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regulatory cells. One might seek to avoid induction of these
suppressors by specifically targeting vaccination attempts
toward myeloid DCs. It is unknown at the present time
what the comparative contribution in vivo each of these
regulatory populations makes to self-tolerance as a whole.
Knockdown of FOXP3 expression in T regs offers the
possibility of shedding new light upon this question.
There no doubt exist, multiple mechanisms via which the
immune system creates the phenomena of immunodominant self-tolerance. To initiate an effective antineoplastic immune response, however, it seems likely that
we need not target all or even a majority of these
mechanisms. It would be desirable from a clinical
perspective to shift the balance, only just so much as to
break peripheral tolerance enough to permit active tumor
immunity. It seems plausible that local RNAi-mediated
knockdown of FOXP3-dependent T reg function might
lower the bar of immune tolerance enough, as to allow
presentation of introduced tumor associated antigens by
APCs, and subsequent clonal proliferation of tumorreactive lymphocytes. The possibility of initiating a
systemic immune response hints that local suppression of
T regs, in combination with relevant tumor associated
antigen exposure, may in fact offer the prospect of
impacting disseminated neoplasms. Such a reaction would
need to attain sufficient momentum as to overcome the
individual regulatory microenvironments surrounding each
tumor mass, including FOXP3-negative IL-10-producing
cells. It may be revealed, however, that FOXP3-dependent
lymphocytes contribute, in a more general sense, to
producing a systemic climate conducive toward immunosuppression, which can be substantially influenced via the
selective targeting of this important protein in vivo.
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Department of Chemistry and Biochemistry Norfolk
Virginia, Old Dominion University, Hampton, VA, USA
E-mail: nklai001@odu.edu

Cancer Gene Therapy

References
1 Curiel T, Cukos G, Zou L, Alvarex X, Cheng P, Mottram P
et al. Specific recruitment of regulatory T cells in ovarian
carcinoma fosters immune privilege and predicts reduced
survival. Nat Med 2004; 9: 942–950.
2 Klebanoff C, Khong H, Antony P, Palmer D, Restifo N.
Sinks Suppressors, and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends
Immunol 2005; 26: 111–117.
3 Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T,
Nakayama E. Tumor rejection by in vivo administration of
anti-CD25 monoclonal antibody. Cancer Res 1999; 59: 3128–
3133.
4 Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295–307.
5 Ochi H, Abraham M, Ishikawa H, Frenkel D, Yang K, Basso
A et al. Oral CD-3 specific antibody uppresses autoimmune
encephalomyelitis by inducing CD 4-CD25 LAP+ T cells.
Nat Med 2006; 6: 627–634.
6 Berttelli E, Dastrange M, Oukka M. Foxp3 interacts with
nuclear factor of activated T cells and NF-kB to repress
cytokine gene expression and effector function of T helper
cells. PNAS 2005; 102: 5138–5143.
7 den Brok M, Sutmuller R, Nierkens S, Bennink E, Frielink C,
Toonen L et al. Efficient loading of dendritic cells following
cryo and radio frequency ablation in combination with
immune modulation induces anti-tumor immunity. BJC
2006; 95: 896–905.
8 Mincheff M, Serguei Z, Altankova I, Tchakarov S, Pogribnyy
P, Makogonenko Y et al. Depletion of CD 25+ cells
from human enriched fraction eliminates immunodominance
during priming with dendritic cells genetically modified
to express a secreted protein. Cancer Gene Ther 2005; 12:
185–197.
9 Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P et al.
Plasmacytoid dendritic cells induce CD 8+ regulatory T
cells in human ovarian carcinoma. Cancer Res 2005; 65:
520–526.

